The decision was based on findings from the Phase III PANOVA-3 clinical trial.

NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité ...

Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy ...

Novocure’ s shares stumbled nearly 20% after the company disclosed it failed to meet its primary endpoints in the TRIDENT ...

Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, ...

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...

Novocure Ltd. NVCR on Thursday reported topline results from its Phase 3 TRIDENT study. The data showed that starting Tumor Treating Fields (TTFields) therapy during chemoradiation did not ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann ...

Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM ...

Novocure shareholders woke up to the pleasant news that Piper Sandler's Jason Bednar upped his recommendation on Novocure well before market open that day. Bednar has removed his previous neutral tag ...